Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Conversion disorder

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    44 result(s) found for: Conversion disorder. Displaying page 2 of 3.
    « Previous 1  2  3  Next»
    EudraCT Number: 2012-000972-40 Sponsor Protocol Number: MK-6621-055 Start Date*: 2012-08-20
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Multicentered, Randomized, Open-Label, Pragmatic Use Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation.
    Medical condition: Atrial Fibrilation
    Disease: Version SOC Term Classification Code Term Level
    15.0 10007541 - Cardiac disorders 10007545 Cardiac dysrhythmias LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2021-003434-36 Sponsor Protocol Number: GS-US-590-6154 Start Date*: 2022-03-23
    Sponsor Name:Gilead Sciences Inc
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Magrolimab versus Placebo in Combination with Venetoclax and Azacitidine in Newly Diagnosed, Prev...
    Medical condition: Acute Myeloid Leukemia
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) DE (Completed) HU (Prematurely Ended) BE (Completed) FR (Completed) AT (Prematurely Ended) PL (Prematurely Ended) NL (Completed) IT (Prematurely Ended) ES (Prematurely Ended) NO (Completed)
    Trial results: View results
    EudraCT Number: 2004-000870-29 Sponsor Protocol Number: RISSCH3001 Start Date*: 2004-11-04
    Sponsor Name:Janssen-Cilag Medical Affairs EMEA
    Full Title: CONSTATRE Risperdal Consta Trial of Relapse Prevention and Effectiveness
    Medical condition: SCHIZOPHRENIA, SCHIZOAFFECTIVE DISORDER
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Completed) ES (Completed) AT (Completed) SE (Completed) CZ (Completed) LV (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2007-005439-27 Sponsor Protocol Number: SP902 Start Date*: 2009-02-16
    Sponsor Name:UCB BIOSCIENCES, Inc.
    Full Title: A Historical-controlled, Multicenter, Double-blind, Randomized Trial to Assess the Efficacy and Safety of Conversion to Lacosamide 400mg/day Monotherapy in Subjects with Partial-onset Seizures
    Medical condition: Partial-onset seizures (with or without secondary generalization)
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029205 - Nervous system disorders 10040703 Simple partial seizures PT
    14.0 10029205 - Nervous system disorders 10010145 Complex partial seizures PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IE (Completed) ES (Completed) AT (Completed) DK (Completed) PT (Not Authorised) IT (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-003371-18 Sponsor Protocol Number: MAA-202 Start Date*: 2021-03-30
    Sponsor Name:Catalyst Biosciences, Inc.
    Full Title: Phase 1/2 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Efficacy of Marzeptacog alfa (activated) in Treatment of Episodic Bleeding in Subjects with Inherited Bleeding Disorders
    Medical condition: Factor VII deficiency, Glanzmann thrombasthenia (GT) and Hemophilia A with inhibitors on emicizumab prophylaxis (HAwI-E)
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10060612 Hemophilia A LLT
    20.0 10010331 - Congenital, familial and genetic disorders 10016079 Factor VII deficiency PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-003002-26 Sponsor Protocol Number: P051032 Start Date*: 2007-02-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: Evaluation du traitement par corticothérapie systémique ou par interféron alpha2a au cours de la Birdshot rétinochoroïdopathie compliquée d'oedeme maculaire
    Medical condition: Traitement de la Birdshot rétinochoroïdopathie.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10063118 Birdshot rétinochoroïdopathie PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004714-27 Sponsor Protocol Number: N01258 Start Date*: 2011-10-05
    Sponsor Name:UCB Biosciences, Inc.
    Full Title: A Multicenter, Open-label, Four-arm, Randomized trial, Evaluating the Safety and Tolerability of Brivaracetam Intravenous Infusion and Bolus, Administered in BID Regimen as an Adjunctive Antiepilep...
    Medical condition: Epilepsy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10015037 Epilepsy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2008-005294-35 Sponsor Protocol Number: ELDERLY-NEXT Start Date*: 2009-02-26
    Sponsor Name:AZIENDA USL 6 LIVORNO ZONA LIVORNESE
    Full Title: Multicenter Phase II study of Sequential Chemotherapy with Cisplatin/Gemcitabine Followed by Docetaxel in Elderly Advanced Non-Small-Cell Lung Cancer (NSCLC) patients
    Medical condition: elderly advanced NSCLC patients
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001160 LLT
    9.1 10001162 LLT
    9.1 10025031 LLT
    9.1 10001160 LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000903-26 Sponsor Protocol Number: GBT440-032 Start Date*: 2022-02-02
    Sponsor Name:Global Blood Therapeutics, Inc.
    Full Title: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2)
    Medical condition: Sickle Cell Disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 10010331 - Congenital, familial and genetic disorders 10040644 Sickle cell disease PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed) GB (GB - no longer in EU/EEA) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-000426-20 Sponsor Protocol Number: 15-006 Start Date*: 2016-09-05
    Sponsor Name:Jazz Pharmaceuticals
    Full Title: A Double-Blind, Placebo-Controlled, Randomized-Withdrawal, Multicenter Study of the Efficacy and Safety of JZP-258 in Subjects with Narcolepsy with Cataplexy
    Medical condition: Treatment of cataplexy in narcolepsy Treatment of excessive daytime sleepiness (EDS) in narcolepsy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10015595 Excessive daytime sleepiness LLT
    20.0 100000004852 10007738 Cataplexy and narcolepsy LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) DE (Completed) ES (Completed) FR (Completed) BE (Completed) FI (Completed) HR (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000120-33 Sponsor Protocol Number: BAY86-5321/16598 Start Date*: 2015-08-26
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label, randomized, active-controlled, parallel-group, Phase-3b study of the efficacy, safety, and tolerability of 2 mg aflibercept administered by intravitreal injections using two differen...
    Medical condition: Neovascular Age-Related Macular Degeneration (nAMD)
    Disease: Version SOC Term Classification Code Term Level
    18.1 10015919 - Eye disorders 10071129 Neovascular age-related macular degeneration PT
    18.1 10015919 - Eye disorders 10015919 Eye disorders SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) CZ (Completed) SK (Completed) PT (Completed) LT (Completed) AT (Completed) GB (GB - no longer in EU/EEA) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-002392-35 Sponsor Protocol Number: KRT-232-113 Start Date*: 2021-02-05
    Sponsor Name:Kartos Therapeutics, Inc.
    Full Title: An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 with TL-895 in Subjects with Relapsed/Refractory Myelofibrosis and of KRT-232 in Janus-associated Kinase Inhibitor...
    Medical condition: Relapsed/Refractory Myelofibrosis and Janus-associated Kinase Inhibitor-Intolerant Myelofibrosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028537 Myelofibrosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) HU (Prematurely Ended) PL (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) BG (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-004327-35 Sponsor Protocol Number: CL2-18986-009 Start Date*: 2005-04-07
    Sponsor Name:Institut de Recherches Internationales Servier
    Full Title: Efficacy of 15 mg and 50 mg of S 18986 on cognitive symptoms in Mild Cognitive Impairment patients treated over a 12-month oral administration period. An international multicentre, 3 parallel grou...
    Medical condition: Mild Cognitive Impairment
    Disease: Version SOC Term Classification Code Term Level
    5.1 10027175 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004734-37 Sponsor Protocol Number: NORM-01 Start Date*: 2021-12-14
    Sponsor Name:Octapharma Pharmazeutika Prod.Ges.m.b.H
    Full Title: Prospective, open-label, single-arm, multicentre Phase 3 study to evaluate the pharmacokinetics, efficacy, tolerability, and safety of subcutaneous human immunoglobulin (Newnorm) in patients with p...
    Medical condition: Primary Immunodeficiency Diseases
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10064859 Primary immunodeficiency syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) SK (Trial now transitioned) PL (Trial now transitioned) HU (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2005-000517-36 Sponsor Protocol Number: CRAD001H2401 Start Date*: 2005-09-21
    Sponsor Name:Novartis Pharma Services AG
    Full Title: RESCUE Study (Certican in Liver Transplant Recipients with Renal Insufficiency) A 6-month, multicenter, randomized, open-label study of safety and efficacy of Certican-based regimen versus CNI-b...
    Medical condition: maintenance of liver transplant
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) BE (Completed) ES (Completed) IT (Completed) FI (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001321-68 Sponsor Protocol Number: B1761026 Start Date*: 2018-05-22
    Sponsor Name:Pfizer, Inc.
    Full Title: Gemtuzumab Ozogamicin (mylotarg (registered)) Expanded Access Protocol For Treatment Of Patients In The United States With Relapsed/refractory Acute Myelogenous Leukemia Who May Benefit From Treatm...
    Medical condition: Acute Myelogenous Leukemia, including myelodysplastic syndrome and acute promyelocytic leukemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2012-003996-20 Sponsor Protocol Number: ALK9072-003EXT Start Date*: 2013-03-28
    Sponsor Name:Alkermes, Inc.
    Full Title: A Phase 3, Multicenter, Extension of Study ALK9072-003 to Assess the Long-term Safety and Durability of Effect of ALKS 9072 in Subjects with Stable Schizophrenia
    Medical condition: stable schizophrenia
    Disease: Version SOC Term Classification Code Term Level
    17.1 10037175 - Psychiatric disorders 10039626 Schizophrenia PT
    17.1 10037175 - Psychiatric disorders 10009134 Chronic schizophrenia LLT
    17.1 10037175 - Psychiatric disorders 10039632 Schizophrenia NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BG (Completed)
    Trial results: View results
    EudraCT Number: 2016-003544-37 Sponsor Protocol Number: ABUHB/01/0816/1 Start Date*: 2016-11-30
    Sponsor Name:Aneurin Bevan University Health Board
    Full Title: Perineural Local Anaesthetic Catheter aftEr Major lowEr limb amputatioN Trial (PLACEMENT)
    Medical condition: Analgesia for lower limb amputation for peripheral vascular disease (PVD)
    Disease: Version SOC Term Classification Code Term Level
    19.1 10042613 - Surgical and medical procedures 10042613 Surgical and medical procedures SOC
    19.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    19.1 10018065 - General disorders and administration site conditions 10018065 General disorders and administration site conditions SOC
    19.1 10022117 - Injury, poisoning and procedural complications 10022117 Injury, poisoning and procedural complications SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-002780-17 Sponsor Protocol Number: ND0612-315 Start Date*: 2018-05-21
    Sponsor Name:NeuroDerm Ltd.
    Full Title: A Pivotal, Open-Label, Randomized, Crossover, Four Sequences Study in Male and Female Patients with Advanced Parkinson’s Disease to Assess the Relative Bioavailability of Levodopa Administered as N...
    Medical condition: Parkinson’s Disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10034005 Parkinson's disease and parkinsonism HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2009-013165-25 Sponsor Protocol Number: TAK-491_109 Start Date*: 2010-02-26
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Comparative Single-Dose Pharmacokinetic and Safety Study of TAK-491 Between Infants, Children, and Adolescents with Hypertension and Healthy Adults
    Medical condition: Hypertension
    Disease: Version SOC Term Classification Code Term Level
    14.1 10047065 - Vascular disorders 10020772 Hypertension PT
    14.1 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    « Previous 1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 24 07:40:09 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA